Capricor Therapeutics: Update on Deramiocel (CAP-1002) for Duchenne Cardiomyopathy

Please join PPMD and Capricor Therapeutics for a community webinar on Thursday, March 6, 2025 at 1PM ET. The Capricor team will provide a current update on the company’s Biologics License Application (BLA) seeking full approval of deramiocel (CAP-1002), Capricor’s novel cell therapy for the treatment of patients diagnosed with Duchenne cardiomyopathy.

Please submit your questions in advance.
Sign in to Google to save your progress. Learn more
Name *
Email *
Question *
Submit
Clear form
Never submit passwords through Google Forms.
This form was created inside of Parent Project Muscular Dystrophy.

Does this form look suspicious? Report

Google Forms